Biological Evaluation of Dinuclear Platinum(II) Complexes with Aromatic N-Heterocycles as Bridging Ligands
Abstract
:1. Introduction
2. Synthesis of Dinuclear Platinum(II) Complexes, [{Pt(L)Cl}2(μ-Bridging Ligand)]2+
3. Dinuclear Platinum(II) Complexes Have a Potent Antitumor Effect In Vitro
4. Dinuclear Platinum(II) Complexes Induce Apoptosis of Target Cells
5. Dinuclear Platinum(II) Complexes Affect Cell Proliferation
6. Dinuclear Platinum(II) Complexes Inhibit Migratory Capacity of Target Tumor Cells
7. Dinuclear Platinum(II) Complexes Exhibit Strong Antitumor Effects with Reduced Side Effects In Vivo
8. Antimicrobial Activity of Dinuclear Platinum(II) Complexes
9. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Orvig, C.; Abrams, M.J. Medicinal inorganic chemistry: Introduction. Chem. Rev. 1999, 99, 2201–2203. [Google Scholar] [CrossRef] [PubMed]
- Lu, Q. Molecular Reaction Mechanisms of Combination Treatments of Low-Dose Cisplatin with Radiotherapy and Photodynamic Therapy. J. Med. Chem. 2007, 50, 2601–2604. [Google Scholar] [CrossRef] [PubMed]
- Todd, R.C.; Lippard, S.J. Inhibition of transcription by platinum antitumor compounds. Metallomics 2009, 1, 280–291. [Google Scholar] [CrossRef] [PubMed]
- Wang, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005, 4, 307–320. [Google Scholar] [CrossRef] [PubMed]
- Reishus, J.W.; Martin, D.S., Jr. cis-Dichlorodiammineplatinum(II). Acid Hydrolysis and Isotopic Exchange of the Chloride Ligands. J. Am. Chem. Soc. 1961, 83, 2457–2462. [Google Scholar] [CrossRef]
- Rabik, C.A.; Dolan, M.E. Molecular Mechanisms of Resistance and Toxicity Associated with Platinating Agents. Cancer Treat. Rev. 2007, 33, 9–23. [Google Scholar] [CrossRef]
- Graf, N.; Ang, W.H.; Zhu, G.; Myint, M.; Lippard, S.J. Role of Endonucleases XPF and XPG in ucleotide Excision Repair of Platinated DNA and Cisplatin/Oxaliplatin Cytotoxicity. ChemBioChem 2011, 12, 1115–1123. [Google Scholar] [CrossRef]
- Bianchi, M.E.; Beltrame, M.; Paonessa, G. Specific Recognition of Cruciform DNA by Nuclear Protein HMG1. Science 1989, 243, 1056–1059. [Google Scholar] [CrossRef]
- Rybak, L.; Whitworth, C.; Mukherjea, D.; Ramkumar, V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear. Res. 2007, 226, 157–167. [Google Scholar] [CrossRef]
- Brabec, V.; Kasparkova, J. Modifications of DNA by platinum complexes: Relation to resistance of tumors to platinum antitumor drugs. Drug Resist. Updat. 2005, 8, 131–146. [Google Scholar] [CrossRef]
- McWhinney, S.R.; Goldberg, R.M.; McLeod, H.L. Platinum neurotoxicity pharmacogenetics. Mol. Cancer 2009, 8, 10–16. [Google Scholar] [CrossRef] [PubMed]
- Ahn, J.H.; Kang, Y.K.; Kim, T.W.; Bahng, H.; Chang, H.M.; Kang, W.C.; Kim, W.K.; Lee, J.S.; Park, J.S. Nephrotoxicity of heptaplatin: A randomized comparison with cisplatin in advanced gastric cancer. Cancer Chemother. Pharmacol. 2002, 50, 104–110. [Google Scholar] [CrossRef]
- Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7, 573–584. [Google Scholar] [CrossRef] [PubMed]
- Barefoot, R.R. Speciation of platinum compounds: A review of recent applications in studies of platinum anticancer drugs. J. Chromatogr. B Biomed. Sci. Appl. 2001, 751, 205–211. [Google Scholar] [CrossRef] [PubMed]
- Johnstone, T.C.; Suntharalingam, K.; Lippard, S.J. The Next Generation of Platinum Drugs: Targeted Platinum(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem. Rev. 2016, 116, 3436–3486. [Google Scholar] [CrossRef] [PubMed]
- Lippert, B. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug; Wiley-VCH: Zürich, Switzerland, 1991. [Google Scholar]
- O’Dowd, P.D.; Sutcliffe, D.F.; Griffith, D.M. Oxaliplatin and its derivatives—An overview. Coord. Chem. Rev. 2023, 497, 215439. [Google Scholar] [CrossRef]
- Kostova, I. Platinum complexes as anticancer agents. Recent Pat. Anticancer. Drug Discov. 2006, 1, 1–22. [Google Scholar] [CrossRef] [PubMed]
- Boulikas, T.; Vougiouka, M. Cisplatin and platinum drugs at the molecular level. Onkol. Rep. 2003, 10, 1663–1682. [Google Scholar] [CrossRef]
- Pasetto, L.M.; D’Andrea, M.R.; Brandes, A.A.; Rossi, E.; Monfardini, S. The development of platinum compounds and their possible combination. Crit. Rev. Oncol. Hematol. 2006, 60, 59–75. [Google Scholar] [CrossRef]
- Kašpárková, J.; Vojtísková, M.; Natile, G.; Brabec, V. Unique Properties of DNA Interstrand Cross-Links of Antitumor Oxaliplatin and the Effect of Chirality of the Carrier Ligand. Chem. Eur. J. 2008, 14, 1330–1341. [Google Scholar] [CrossRef]
- Niioka, T.; Uno, T.; Yasui-Furukori, N.; Takahata, T.; Shimizu, M.; Sugawara, K.; Tateishi, T. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma. Cancer Chemother. Pharmacol. 2007, 59, 575–580. [Google Scholar] [CrossRef] [PubMed]
- Wheate, N.J.; Walker, S.; Craig, G.E.; Oun, R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010, 39, 8113–8127. [Google Scholar] [CrossRef] [PubMed]
- Shimada, M.; Itamochi, H.; Kigawa, J. Nedaplatin: A cisplatin derivative in cancer chemotherapy. Cancer Manag. Res. 2013, 8, 67–76. [Google Scholar] [CrossRef]
- Ota, K.; Wakui, A.; Majima, H.; Niitani, H.; Inuyama, Y.; Ogawa, M.; Ariyoshi, Y.; Yoshida, O.; Taguchi, T.; Kimura, I. Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II). Gan Kagaku Ryoho. Cancer Chemother. 1992, 19, 855–861. [Google Scholar]
- Uehara, T.; Yamate, J.; Torii, M.; Maruyama, T. Comparative nephrotoxicity of cisplatin and nedaplatin: Mechanisms and histopathological characteristics. J. Toxicol. Pathol. 2011, 24, 87–94. [Google Scholar] [CrossRef] [PubMed]
- Li, X.-J.; Nie, P.; Herdewijn, P.; Sun, J.-G. Unlocking the synthetic approaches and clinical application of approved small-molecule drugs for gastrointestinal cancer treatment: A comprehensive exploration. Eur. J. Med. Chem. 2023, 262, 115928. [Google Scholar] [CrossRef]
- McKeage, M.J. Lobaplatin: A new antitumour platinum drug. Expert Opin. Inv. Drug. 2001, 10, 119–128. [Google Scholar] [CrossRef]
- Saris, C.P.; van de Vaart, P.J.; Rietbroek, R.C.; Blommaert, F.A. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogen 1996, 17, 2763–2769. [Google Scholar] [CrossRef]
- Wexselblatt, E.; Gibson, D. What do we know about the reduction of Pt(IV) pro-drugs? J. Inorg. Biochem. 2012, 117, 220–229. [Google Scholar] [CrossRef]
- Gibson, D. Platinum(IV) anticancer prodrugs—Hypotheses and facts. Dalton Trans. 2016, 45, 12983–12991. [Google Scholar] [CrossRef]
- Kenny, R.G.; Chuah, S.W.; Crawford, A.; Marmion, C.J. Platinum(IV) Prodrugs—A Step Closer to Ehrlich’s Vision? Eur. J. Inorg. Chem. 2017, 2017, 1596–1612. [Google Scholar] [CrossRef]
- Zhang, C.X.; Lippard, S.J. New metal complexes as potential therapeutics. Curr. Opin. Chem. Biol. 2003, 7, 481–489. [Google Scholar] [CrossRef] [PubMed]
- Bruijnincx, P.C.A.; Sadler, P.J. New trends for metal complexes with anticancer activity. Curr. Opin. Chem. Biol. 2008, 12, 197–206. [Google Scholar] [CrossRef] [PubMed]
- Sedletska, Y.; Giraud-Panis, M.J.; Malinge, J.M. Cisplatin Is a DNA-Damaging Antitumour Compound Triggering Multifactorial Biochemical Responses in Cancer Cells: Importance of Apoptotic Pathways. Curr. Med. Chem. Anticancer Agents 2005, 5, 251–265. [Google Scholar] [CrossRef] [PubMed]
- Lovejoy, K.S.; Lippard, S.J. Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting. Dalton Trans. 2009, 48, 10651–10659. [Google Scholar] [CrossRef]
- Farrell, N. Metal complexes as drugs and chemotherapeutic agents. Compr. Coord. Chem. 2003, 9, 809–840. [Google Scholar]
- Zhang, J.; Wang, L.; Xing, Z.; Liu, D.; Sun, J.; Li, X.; Zhang, Y. Status of Bi- and Multi-Nuclear Platinum Anticancer Drug Development. Anticancer Agents Med. Chem. 2010, 10, 272–282. [Google Scholar] [CrossRef] [PubMed]
- Qu, Y.; Rauter, H.; Fontes, A.P.S.; Bandarage, R.; Kelland, L.R.; Farrell, N. Synthesis, Characterization, and Cytotoxicity of Trifunctional Dinuclear Platinum Complexes: Comparison of Effects of Geometry and Polyfunctionality on Biological Activity. J. Med. Chem. 2000, 43, 3189–3192. [Google Scholar]
- Komeda, S.; Lutz, M.; Spek, A.L.; Chikuma, M.; Reedijk, J. New Antitumor-Active Azole-Bridged Dinuclear Platinum(II) Complexes: Synthesis, Characterization, Crystal Structures, and Cytotoxic Studies. Inorg. Chem. 2000, 39, 4230–4236. [Google Scholar] [CrossRef]
- Rajković, S.; Rychlewska, U.; Warzajtis, B.; Asanin, D.P.; Živkovic, M.D.; Djuran, M.I. Disparate behavior of pyrazine and pyridazine platinum(II) dimers in the hydrolysis of histidine- and methionine-containing peptides and unique crystal structure of {[Pt(en)Cl]2(μ-pydz)}Cl2 with a pair of NH⋯Cl−⋯HN hydrogen bonds supporting the pyridazine bridge. Polyhedron 2014, 67, 279–285. [Google Scholar]
- Komeda, S.; Ohishi, H.; Yamane, H.; Harikawa, M.; Sakaguchi, K.-I.; Chikuma, M. An NMR study and crystal structure of [{cis-Pt(NH3)2(9EtG-κN7)}2(µ-pz)][NO3]3 (9EtG = 9-ethylguanine) as a model compound for the 1,2-intrastrand GG crosslink. Dalton Trans. 1999, 17, 2959–2962. [Google Scholar] [CrossRef]
- Franich, A.A.; Đorđević, I.S.; Živković, M.D.; Rajković, S.; Janjić, G.V.; Djuran, M.I. Dinuclear platinum(II) complexes as the pattern for phosphate backbone binding: A new perspective for recognition of binding modes to DNA. J. Biol. Inorg. Chem. 2022, 27, 65–79. [Google Scholar] [CrossRef] [PubMed]
- Orlandi, L.; Colella, G.; Bearzatto, A.; Abolafio, G.; Manzotti, C.; Daidone, M.G.; Zaffaroni, N. Effects of a novel trinuclear platinum complex in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines: Interference with cell cycle progression and induction of apoptosis. Eur. J. Cancer 2001, 37, 649–659. [Google Scholar] [CrossRef]
- Colella, G.; Pennati, M.; Bearzatto, A.; Leone, R.; Colangelo, D.; Manzotti, C.; Daidone, M.G.; Zaffaroni, N. Activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplatin: Cytotoxicity and induction and gene-specific repair of DNA lesions. Br. J. Cancer 2001, 84, 1387–1390. [Google Scholar] [CrossRef]
- Komeda, S.; Moulaei, T.; Woods, K.K.; Chikuma, M.; Farrell, N.P.; Williams, L.D. A Third Mode of DNA Binding: Phosphate Clamps by a Polynuclear Platinum Complex. J. Am. Chem. Soc. 2006, 128, 16092–16103. [Google Scholar] [CrossRef] [PubMed]
- Alessio, E. Bioinorganic Medicinal Chemistry; Wiley-VCH Verlag GmbH & Co.: Weinheim, Germany, 2011. [Google Scholar]
- Manzotti, C.; Pratesi, G.; Menta, E.; Di Domenico, R.; Cavalletti, E.; Fiebig, H.H.; Kelland, L.R.; Farrell, N.; Polizzi, D.; Supino, R.; et al. BBR 3464: A Novel Triplatinum Complex, Exhibiting a Preclinical Profile of Antitumor Efficacy Different from Cisplatin. Clin. Cancer Res. 2000, 6, 2626–2634. [Google Scholar] [PubMed]
- Jodrell, D.I.; Evans, T.R.; Steward, W.; Cameron, D.; Prendiville, J.; Aschele, C.; Noberasco, C.; Lind, M.; Carmichael, J.; Dobbs, N.; et al. Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. Eur. J. Cancer 2004, 40, 1872–1877. [Google Scholar] [CrossRef] [PubMed]
- Hohmann, H.; van Eldik, R. Rate and equilibrium data for substitution reactions of diaqua(ethylenediamine)palladium(II) with chloride in aqueous solution. Inorg. Chim. Acta 1990, 17, 87–92. [Google Scholar] [CrossRef]
- Summa, N.; Soldatovic, T.; Dahlenburg, L.; Bugarcic, Z.D.; van Eldik, R. The impact of different chelating leaving groups on the substitution kinetics of mononuclear Platinum(II)(1,2-trans-R,Rdiaminocyclohexane)(X-Y) complexes. J. Biol. Inorg. Chem. 2007, 12, 461–475. [Google Scholar] [CrossRef]
- Zivkovic, M.D.; Asanin, D.P.; Rajkovic, S.; Djuran, M.I. Hydrolysis of the amide bond in N-acetylated L-methionylglycine catalyzed by various platinum(II) complexes under physiologically relevant conditions. Polyhedron 2011, 30, 947–952. [Google Scholar] [CrossRef]
- Dhara, S.C. A rapid method for the synthesis of cis-[Pt(NH3)2Cl2]. Indian J. Chem. 1970, 8, 193–194. [Google Scholar]
- Mahal, G.; Van Eldik, R. Kinetics and mechanism of the formation, aquation, and base hydrolysis reactions of a series of monodentate carbonato complexes of palladium(II). Inorg. Chem. 1985, 24, 4165–4170. [Google Scholar] [CrossRef]
- Konovalov, B.; Živković, M.D.; Milovanović, J.Z.; Djordjević, D.B.; Arsenijević, A.N.; Vasić, I.R.; Janjić, G.V.; Franich, A.; Manojlović, D.; Skrivanj, S.; et al. Synthesis, cytotoxic activity and DNA interaction studies of new dinuclear platinum(II) complexes with an aromatic 1,5-naphthyridine bridging ligand: DNA binding mode of polynuclear platinum(II) complexes in relation to the complex structure. Dalton Trans. 2018, 47, 15091–15102. [Google Scholar] [CrossRef] [PubMed]
- Konovalov, B.; Franich, A.A.; Jovanović, M.; Jurisević, M.; Gajović, N.; Jovanović, M.; Arsenijević, N.; Maric, V.; Jovanović, I.; Živković, M.D.; et al. Synthesis, DNA-/bovine serum albumin-binding affinity, and cytotoxicity of dinuclear platinum (II) complexes with 1, 6-naphthyridine-bridging ligand. Appl. Organomet. Chem. 2021, 35, e6112. [Google Scholar] [CrossRef]
- Vasić, I.; Rajković, S.; Arsenijević, A.; Milovanović, M.; Arsenijević, N.; Milovanović, J.; Živković, M.D. In vitro and in vivoactivity of series of cationic dinuclearPlatinum(II) complexes. J. Inorg. Biochem. 2021, 225, 111619. [Google Scholar] [CrossRef] [PubMed]
- Kalayda, G.; Komeda, S.; Ikeda, K.; Sato, T.; Chikuma, M.; Reedijk, J. Synthesis, Structure, and Biological Activity of New Azine-Bridged Dinuclear Platinum(II) Complexes—A New Class of Anticancer Compounds. Eur. J. Inorg. Chem. 2003, 2003, 4347–4355. [Google Scholar] [CrossRef]
- Zornić, S.; Simović Marković, B.; Franich, A.A.; Živković, M.D.; Luković, B.; Arsenijević, N.N.; Radosavljević, G.D.; Rajković, S.; Pantić, J. Characterization, modes of interactions with DNA/BSA biomolecules and anti-tumor activity of newly synthesized dinuclear platinum(II) complexes with pyridazine bridging ligand. J. Biol. Inorg. Chem. 2024, 29, 51–73. [Google Scholar] [CrossRef] [PubMed]
- Komeda, S.; Kalayda, G.V.; Lutz, M.H.; Spek, A.L.; Yamanaka, Y.; Sato, T.; Chikuma, M.; Reedijk, J. New Isomeric Azine-Bridged Dinuclear Platinum(II) Complexes Circumvent Cross-Resistance to Cisplatin. J. Med. Chem. 2003, 46, 1210–1219. [Google Scholar] [CrossRef] [PubMed]
- Lirvinov, V.P. Advances in the Chemistry of Naphthyridines. Adv. Heterocycl. Chem. 2006, 91, 189–300. [Google Scholar]
- Suresh, T.; Kumar, R.N.; Mohan, P.S. Synthesis and antibacterial activity of 8-methyl benzo[b]naphtho[f][1,6]-naphthyridines. Asian J. Chem. 2003, 15, 855–859. [Google Scholar]
- Ruchelman, A.L.; Singh, S.K.; Ray, A.W.X.H.; Yang, Y.-M.; Li, T.-K.; Lin, A.; Lin, L.F.; LaVoie, E.J. 5H-Dibenzo[c,h]1,6-naphthyridin-6-ones: Novel topoisomerase I-Targeting anticancer agents with potent cytotoxic activity. Bioorg. Med. Chem. 2003, 11, 2061–2073. [Google Scholar] [CrossRef] [PubMed]
- Madaan, A.; Verma, R.; Kumar, V.; Singh, A.T.; Jain, S.K.; Jaggi, M. 1,8-Naphthyridine Derivatives: A Review of Multiple Biological Activities. Arch. Pharm. 2015, 348, 837–860. [Google Scholar] [CrossRef] [PubMed]
- Graf, M.; Gothe, Z.; Metzler-Nolte, N.; Sünkel, K. Cyclometalated Iridium(III) and Rhodium(III) Complexes Containing Naphthyridine Ligands: Synthesis, Characterization and Biological Studies. Anorg. Allg. Chem. 2017, 643, 306–310. [Google Scholar] [CrossRef]
- Chaudhry, G.E.; Md Akim, A.; Sung, Y.Y.; Sifzizul, T.M.T. Cancer and apoptosis: The apoptotic activity of plant and marine natural products and their potential as targeted cancer therapeutics. Front. Pharmacol. 2022, 13, 842376. [Google Scholar] [CrossRef] [PubMed]
- Jan, R.; Chaudhry, G.E. Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics. Adv. Pharm. Bull. 2019, 9, 205–218. [Google Scholar] [CrossRef] [PubMed]
- Urbani, A.; Prosdocimi, E.; Carrer, A.; Checchetto, V.; Szabò, I. Mitochondrial Ion Channels of the Inner Membrane and Their Regulation in Cell Death Signaling. Front. Cell Dev. Biol. 2021, 8, 620081. [Google Scholar] [CrossRef]
- Kim, R.; Kin, T.; Beck, W.T. Impact of Complex Apoptotic Signaling Pathways on Cancer Cell Sensitivity to Therapy. Cancers 2024, 16, 984. [Google Scholar] [CrossRef] [PubMed]
- Pfeffer, C.M.; Singh, A.T.K. Apoptosis: A Target for Anticancer Therapy. Int. J. Mol. Sci. 2018, 19, 448. [Google Scholar] [CrossRef] [PubMed]
- Peng, F.; Liao, M.; Qin, R.; Zhu, S.; Peng, C.; Fu, L.; Chen, Y.; Han, B. Regulated cell death (RCD) in cancer: Key pathways and targeted therapies. Signal Transduct. Target. Ther. 2022, 7, 286. [Google Scholar] [CrossRef]
- Kari, S.; Subramanian, K.; Altomonte, I.A.; Murugesan, A.; Yli-Harja, O.; Kandhavelu, M. Programmed cell death detection methods: A systematic review and a categorical comparison. Apoptosis 2022, 27, 482–508. [Google Scholar] [CrossRef]
- Hussar, P. Apoptosis Regulators Bcl-2 and Caspase-3. Encyclopedia 2022, 2, 1624–1636. [Google Scholar] [CrossRef]
- Yuan, J.; Lan, H.; Jiang, X.; Zeng, D.; Xiao, S. Bcl-2 family: Novel insight into individualized therapy for ovarian cancer (Review). Int. J. Mol. Med. 2020, 46, 1255–1265. [Google Scholar] [CrossRef] [PubMed]
- Kale, J.; Osterlund, E.J.; Andrews, D.W. BCL-2 family proteins: Changing partners in the dance towards death. Cell Death Differ. 2018, 25, 65–80. [Google Scholar] [CrossRef] [PubMed]
- Singh, R.; Letai, A.; Sarosiek, K. Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins. Nat. Rev. Mol. Cell Biol. 2019, 20, 175–193. [Google Scholar] [CrossRef] [PubMed]
- Chen, Z.X.; Pervaiz, S. BCL-2: Pro-or anti-oxidant? Front. Biosci. 2009, 1, 263–268. [Google Scholar]
- Harris, A.L.; Yang, X.; Hegmans, A.; Povirk, L.; Ryan, J.J.; Kelland, L.; Farrell, N.P. Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge. Inorg. Chem. 2005, 44, 9598–9600. [Google Scholar] [CrossRef] [PubMed]
- Suntharalingam, K.; Wilson, J.J.; Lin, W.; Lippard, S.J. A dual-targeting, p53-independent, apoptosis-inducing platinum(II) anticancer complex, [Pt(BDI(QQ))]Cl. Metallomics 2014, 6, 437–443. [Google Scholar] [CrossRef] [PubMed]
- Suntharalingam, K.; Song, Y.; Lippard, S.J. Conjugation of vitamin E analog α-TOS to Pt(IV) complexes for dual-targeting anticancer therapy. Chem. Commun. 2014, 50, 2465–2468. [Google Scholar] [CrossRef] [PubMed]
- Feitelson, M.A.; Arzumanyan, A.; Kulathinal, R.J.; Blain, S.W.; Holcombe, R.F.; Mahajna, J.; Marino, M.; Martinez-Chantar, M.L.; Nawroth, R.; Sanchez-Garcia, I.; et al. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin. Cancer Biol. 2015, 35, S25–S54. [Google Scholar] [CrossRef]
- Soliman, N.A.; Yussif, S.M. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol. Med. 2016, 13, 496–504. [Google Scholar]
- Mrouj, K.; Andrés-Sánchez, N.; Dubra, G.; Singh, P.; Sobecki, M.; Chahar, D.; Al Ghoul, E.; Aznar, A.B.; Prieto, S.; Pirot, N.; et al. Ki-67 regulates global gene expression and promotes sequential stages of carcinogenesis. Proc. Natl. Acad. Sci. USA 2021, 118, e2026507118. [Google Scholar] [CrossRef] [PubMed]
- Williams, G.H.; Stoeber, K. The cell cycle and cancer. J. Pathol. 2012, 226, 352–364. [Google Scholar] [CrossRef] [PubMed]
- Velma, V.; Dasari, S.R.; Tchounwou, P.B. Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells. Biomark. Insights 2016, 11, 113–121. [Google Scholar] [CrossRef] [PubMed]
- Chiang, K.C.; Tsui, K.H.; Chung, L.C.; Yeh, C.N.; Feng, T.H.; Chen, W.T.; Chang, P.L.; Chiang, H.Y.; Juang, H.H. Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways. Sci. Rep. 2014, 4, 5511. [Google Scholar] [CrossRef] [PubMed]
- Liu, Q.; Cao, Y.; Zhou, P.; Gui, S.; Wu, X.; Xia, Y.; Tu, J. Panduratin A Inhibits Cell Proliferation by Inducing G0/G1 Phase Cell Cycle Arrest and Induces Apoptosis in Breast Cancer Cells. Biomol. Ther. 2018, 26, 328–334. [Google Scholar] [CrossRef] [PubMed]
- Jiang, Y.; Wang, X.; Hu, D. Furanodienone induces G0/G1 arrest and causes apoptosis via the ROS/MAPKs-mediated caspase-dependent pathway in human colorectal cancer cells: A study in vitro and in vivo. Cell Death Dis. 2017, 8, e2815. [Google Scholar] [CrossRef] [PubMed]
- Park, C.; Cha, H.J.; Lee, H.; Hwang-Bo, H.; Ji, S.Y.; Kim, M.Y.; Hong, S.H.; Jeong, J.W.; Han, M.H.; Choi, S.H.; et al. Induction of G2/M Cell Cycle Arrest and Apoptosis by Genistein in Human Bladder Cancer T24 Cells through Inhibition of the ROS-Dependent PI3k/Akt Signal Transduction Pathway. Antioxidants 2019, 8, 327. [Google Scholar] [CrossRef] [PubMed]
- Casimiro, M.C.; Crosariol, M.; Loro, E.; Li, Z.; Pestell, R.G. Cyclins and cell cycle control in cancer and disease. Genes Cancer 2012, 3, 649–657. [Google Scholar] [CrossRef] [PubMed]
- Łukasik, P.; Baranowska-Bosiacka, I.; Kulczycka, K.; Gutowska, I. Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action. Int. J. Mol. Sci. 2021, 22, 2806. [Google Scholar] [CrossRef]
- Bai, J.; Li, Y.; Zhang, G. Cell cycle regulation and anticancer drug discovery. Cancer Biol. Med. 2017, 14, 348–362. [Google Scholar]
- Fagundes, R.; Teixeira, L.K. Cyclin E/CDK2: DNA Replication, Replication Stress and Genomic Instability. Front. Cell Dev. Biol. 2021, 9, 774845. [Google Scholar] [CrossRef]
- Montalto, F.I.; De Amicis, F. Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma. Cells 2020, 9, 2648. [Google Scholar] [CrossRef] [PubMed]
- Sun, C.; Wang, G.; Wrighton, K.H.; Lin, H.; Songyang, Z.; Feng, X.H.; Lin, X. Regulation of p27Kip1 phosphorylation and G1 cell cycle progression by protein phosphatase PPM1G. Am. J. Cancer Res. 2016, 6, 2207–2220. [Google Scholar]
- Jha, R.K.; Kouzine, F.; Levens, D. MYC function and regulation in physiological perspective. Front. Cell Dev. Biol. 2023, 11, 1268275. [Google Scholar] [CrossRef]
- Madden, S.K.; de Araujo, A.D.; Gerhardt, M.; Fairlie, D.P.; Mason, J.M. Taking the Myc out of cancer: Toward therapeutic strategies to directly inhibit c-Myc. Mol. Cancer 2021, 20, 3. [Google Scholar] [CrossRef]
- Masaki, T.; Habara, M.; Hanaki, S.; Sato, Y.; Tomiyasu, H.; Miki, Y.; Shimada, M. Calcineurin-mediated dephosphorylation enhances the stability and transactivation of c-Myc. Sci. Rep. 2023, 13, 13116. [Google Scholar] [CrossRef]
- Song, M.; Bode, A.M.; Dong, Z.; Lee, M.H. AKT as a Therapeutic Target for Cancer. Cancer Res. 2019, 79, 1019–1031. [Google Scholar] [CrossRef] [PubMed]
- Zanotelli, M.R.; Zhang, J.; Reinhart-King, C.A. Mechanoresponsive metabolism in cancer cell migration and metastasis. Cell Metab. 2021, 33, 1307–1321. [Google Scholar] [CrossRef] [PubMed]
- Valastyan, S.; Weinberg, R.A. Tumor metastasis: Molecular insights and evolving paradigms. Cell 2011, 147, 275–292. [Google Scholar] [CrossRef]
- Eble, J.A.; Niland, S. The extracellular matrix in tumor progression and metastasis. Clin. Exp. Metastasis 2019, 36, 171–198. [Google Scholar] [CrossRef]
- Bobadilla, A.V.P.; Arévalo, J.; Sarró, E.; Byrne, H.M.; Maini, P.K.; Carraro, T.; Balocco, S.; Meseguer, A.; Alarcón, T. In vitro cell migration quantification method for scratch assays. J. R. Soc. Interface 2019, 16, 20180709. [Google Scholar] [CrossRef] [PubMed]
- Grada, A.; Otero-Vinas, M.; Prieto-Castrillo, F.; Obagi, Z.; Falanga, V. Research Techniques Made Simple: Analysis of Collective Cell Migration Using the Wound Healing Assay. J. Investig. Dermatol. 2017, 137, e11–e16. [Google Scholar] [CrossRef]
- Jonkman, J.E.; Cathcart, J.A.; Xu, F.; Bartolini, M.E.; Amon, J.E.; Stevens, K.M.; Colarusso, P. An introduction to the wound healing assay using live-cell microscopy. Cell Adhes. Migr. 2014, 8, 440–451. [Google Scholar] [CrossRef] [PubMed]
- Bai, X.; Ali, A.; Lv, Z.; Wang, N.; Zhao, X.; Hao, H.; Zhang, Y.; Rahman, F.U. Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways. Eur. J. Med. Chem. 2021, 224, 113689. [Google Scholar] [CrossRef]
- Dimitrijević Stojanović, M.N.; Franich, A.A.; Jurišević, M.M.; Gajović, N.M.; Arsenijević, N.N.; Jovanović, I.P.; Stojanović, B.S.; Mitrović, S.L.; Kljun, J.; Rajković, S.; et al. Platinum(II) complexes with malonic acids: Synthesis, characterization, in vitro and in vivo antitumor activity and interactions with biomolecules. J. Inorg. Biochem. 2022, 231, 111773. [Google Scholar] [CrossRef]
- Cao, H.; Feng, Y.; Chen, L.; Yu, C. Lobaplatin Inhibits Prostate Cancer Proliferation and Migration Through Regulation of BCL2 and BAX. Dose Response 2019, 17, 1559325819850981. [Google Scholar] [CrossRef]
- Semlali, A.; Ajala, I.; Beji, S.; Al-Zharani, M.M.; Rouabhia, M. Synergistic Effect of Anethole and Platinum Drug Cisplatin against Oral Cancer Cell Growth and Migration by Inhibiting MAPKase, Beta-Catenin, and NF-κB Pathways. Pharmaceuticals 2023, 16, 700. [Google Scholar] [CrossRef] [PubMed]
- Czarnomysy, R.; Radomska, D.; Szewczyk, O.K.; Roszczenko, P.; Bielawski, K. Platinum and Palladium Complexes as Promising Sources for Antitumor Treatments. Int. J. Mol. Sci. 2021, 22, 8271. [Google Scholar] [CrossRef] [PubMed]
- Jonker, D.; Rumble, R.B.; Maroun, J. Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer. Curr. Oncol. 2006, 13, 173–814. [Google Scholar] [CrossRef]
- Igea, A.; Martin, O.C.B.; Cooks, T.; Pateras, I.S. Editorial: Infectious disease agents and cancer. Front. Cell Dev. Biol. 2024, 12, 1388423. [Google Scholar] [CrossRef]
- de Martel, C.; Georges, D.; Bray, F.; Ferlay, J.; Clifford, G.M. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob. Health 2020, 8, e180–e190. [Google Scholar] [CrossRef] [PubMed]
- Rosenberg, B.; Van Camp, L.; Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965, 205, 698–699. [Google Scholar] [CrossRef] [PubMed]
- Tkacheva, V.; Sharutin, V.; Sharutina, O.K.; Shlepotina, N.M.; Kolesnikov, O.L.; Shishkova, Y.S.; Peshikova, M.V. Tetravalent Platinum Complexes: Synthesis, Structure, and Antimicrobial Activity. Russ. J. Gen. Chem. 2020, 90, 655–659. [Google Scholar] [CrossRef]
- Frei, A.; Zuegg, J.; Elliott, A.G.; Baker, M.; Braese, S.; Brown, C.; Chen, F.; Dowson, C.G.; Dujardin, G.; Jung, N.; et al. Metal complexes as a promising source for new antibiotics. Chem. Sci. 2020, 11, 2627–2639. [Google Scholar] [CrossRef]
- Frei, A.; Ramu, S.; Lowe, G.J.; Dinh, H.; Semenec, L.; Elliott, A.G.; Zuegg, J.; Deckers, A.; Jung, N.; Bräse, S.; et al. Platinum Cyclooctadiene Complexes with Activity against Gram-positive Bacteria. ChemMedChem 2021, 16, 3165–3171. [Google Scholar] [CrossRef]
- Jawad, W.A.; Balakit, A.A.A.A.H.; Al-Jibouri, M.N.A. Synthesis, Characterization and Antibacterial Activity Study of Cobalt(II), Nickel(II), Copper(II), Palladium(II), Cadmium(II) and Platinum(IV) Complexes with 4-Amino-5-(3,4,5-trimethoxyphenyl)-4H-1,2,4-triazole-3-thione. Indones. J. Chem. 2021, 21, 1514–1525. [Google Scholar] [CrossRef]
General Name | Chemical Structure | Trade Name | Year of Approval |
---|---|---|---|
cisplatin | platinol | 1978 | |
carboplatin | paraplatin | 1989 | |
oxaliplatin | eloxatin | 2002 | |
nedaplatin | aqupla | 1995 | |
heptaplatin | SunPla | 1999 | |
laboplatin | - | 2010 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Luković, D.; Franich, A.A.; Živković, M.D.; Rajković, S.; Stojanović, B.; Gajović, N.; Jurišević, M.; Pavlović, S.; Simović Marković, B.; Jovanović, M.; et al. Biological Evaluation of Dinuclear Platinum(II) Complexes with Aromatic N-Heterocycles as Bridging Ligands. Int. J. Mol. Sci. 2024, 25, 8525. https://doi.org/10.3390/ijms25158525
Luković D, Franich AA, Živković MD, Rajković S, Stojanović B, Gajović N, Jurišević M, Pavlović S, Simović Marković B, Jovanović M, et al. Biological Evaluation of Dinuclear Platinum(II) Complexes with Aromatic N-Heterocycles as Bridging Ligands. International Journal of Molecular Sciences. 2024; 25(15):8525. https://doi.org/10.3390/ijms25158525
Chicago/Turabian StyleLuković, Desimir, Andjela A. Franich, Marija D. Živković, Snežana Rajković, Bojan Stojanović, Nevena Gajović, Milena Jurišević, Slađana Pavlović, Bojana Simović Marković, Marina Jovanović, and et al. 2024. "Biological Evaluation of Dinuclear Platinum(II) Complexes with Aromatic N-Heterocycles as Bridging Ligands" International Journal of Molecular Sciences 25, no. 15: 8525. https://doi.org/10.3390/ijms25158525